BofA analyst Alex Stranahan raised the firm’s price target on Revolution Medicines (RVMD) to $115 from $109 and keeps a Buy rating on the shares. The firm continues to think RevMed has “one of the highest-quality late-stage pipelines across oncology,” with eight registrational trials active or planned in 2026, the analyst tells investors. Peak sales opportunities for daraxonrasib, zoldonrasib, and elironrasib warrant the company’s spending, the analyst added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $144 from $100 at Wells Fargo
- Revolution Medicines: Advancing RAS Inhibitor Pipeline and Strong Cash Runway Support Buy Rating
- Revolution Medicines reports Q4 EPS ($1.86), consensus ($1.56)
- Revolution Medicines sees FY26 operating expenses $1.6B-$1.7B
- Revolution Medicines initiated with an Outperform at Evercore ISI